These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 19549089)
1. Absorption of testosterone gel 1% (Testim) from three different application sites. Guay AT; Smith TM; Offutt LA J Sex Med; 2009 Sep; 6(9):2601-10. PubMed ID: 19549089 [TBL] [Abstract][Full Text] [Related]
2. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels. Blick G Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men. Grober ED; Khera M; Soni SD; Espinoza MG; Lipshultz LI Int J Impot Res; 2008; 20(2):213-7. PubMed ID: 17898800 [TBL] [Abstract][Full Text] [Related]
4. Testim 1% testosterone gel for the treatment of male hypogonadism. Bouloux P Clin Ther; 2005 Mar; 27(3):286-98. PubMed ID: 15878382 [TBL] [Abstract][Full Text] [Related]
5. Review of Testim gel. McNicholas T; Ong T Expert Opin Pharmacother; 2006 Mar; 7(4):477-84. PubMed ID: 16503819 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of the pharmacokinetic profiles of the new testosterone topical gel formulation, Testim, compared to AndroGel. Marbury T; Hamill E; Bachand R; Sebree T; Smith T Biopharm Drug Dispos; 2003 Apr; 24(3):115-20. PubMed ID: 12673669 [TBL] [Abstract][Full Text] [Related]
7. A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. McNicholas TA; Dean JD; Mulder H; Carnegie C; Jones NA BJU Int; 2003 Jan; 91(1):69-74. PubMed ID: 12614254 [TBL] [Abstract][Full Text] [Related]
8. 12-month observation of testosterone replacement effectiveness in a general population of men. Miner MM; Bhattacharya RK; Blick G; Kushner H; Khera M Postgrad Med; 2013 Mar; 125(2):8-18. PubMed ID: 23816767 [TBL] [Abstract][Full Text] [Related]
9. Testosterone replacement therapy among elderly males: the Testim Registry in the US (TRiUS). Bhattacharya RK; Khera M; Blick G; Kushner H; Miner MM Clin Interv Aging; 2012; 7():321-30. PubMed ID: 22956867 [TBL] [Abstract][Full Text] [Related]
10. Improved sexual function with testosterone replacement therapy in hypogonadal men: real-world data from the Testim Registry in the United States (TRiUS). Khera M; Bhattacharya RK; Blick G; Kushner H; Nguyen D; Miner MM J Sex Med; 2011 Nov; 8(11):3204-13. PubMed ID: 21834870 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study. Wang C; Berman N; Longstreth JA; Chuapoco B; Hull L; Steiner B; Faulkner S; Dudley RE; Swerdloff RS J Clin Endocrinol Metab; 2000 Mar; 85(3):964-9. PubMed ID: 10720024 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety study of 1.62% testosterone gel for the treatment of hypogonadal men. Kaufman JM; Miller MG; Garwin JL; Fitzpatrick S; McWhirter C; Brennan JJ J Sex Med; 2011 Jul; 8(7):2079-89. PubMed ID: 21492400 [TBL] [Abstract][Full Text] [Related]
13. Comparison of the steady-state pharmacokinetics, metabolism, and variability of a transdermal testosterone patch versus a transdermal testosterone gel in hypogonadal men. Mazer N; Bell D; Wu J; Fischer J; Cosgrove M; Eilers B; J Sex Med; 2005 Mar; 2(2):213-26. PubMed ID: 16422889 [TBL] [Abstract][Full Text] [Related]
14. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. Swerdloff RS; Wang C; Cunningham G; Dobs A; Iranmanesh A; Matsumoto AM; Snyder PJ; Weber T; Longstreth J; Berman N J Clin Endocrinol Metab; 2000 Dec; 85(12):4500-10. PubMed ID: 11134099 [TBL] [Abstract][Full Text] [Related]
15. Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory. Khera M; Bhattacharya RK; Blick G; Kushner H; Nguyen D; Miner MM J Urol; 2011 Sep; 186(3):1005-11. PubMed ID: 21788049 [TBL] [Abstract][Full Text] [Related]
16. Effect of application site, clothing barrier, and application site washing on testosterone transfer with a 1.62% testosterone gel. Stahlman J; Britto M; Fitzpatrick S; McWhirter C; Testino SA; Brennan JJ; Zumbrunnen TL Curr Med Res Opin; 2012 Feb; 28(2):281-90. PubMed ID: 22188557 [TBL] [Abstract][Full Text] [Related]
17. Testosterone replacement therapy in men with hypogonadism and HIV/AIDS: results from the TRiUS registry. Blick G; Khera M; Bhattacharya RK; Kushner H; Miner MM Postgrad Med; 2013 Mar; 125(2):19-29. PubMed ID: 23816768 [TBL] [Abstract][Full Text] [Related]
18. Serum testosterone levels in non-dosed females after secondary exposure to 1.62% testosterone gel: effects of clothing barrier on testosterone absorption. Stahlman J; Britto M; Fitzpatrick S; McWhirter C; Testino SA; Brennan JJ; Zumbrunnen TL Curr Med Res Opin; 2012 Feb; 28(2):291-301. PubMed ID: 22188558 [TBL] [Abstract][Full Text] [Related]
19. Effects of skin washing on systemic absorption of testosterone in hypogonadal males after administration of 1.62% testosterone gel. Stahlman J; Britto M; Fitzpatrick S; McWhirter C; Testino SA; Brennan JJ; Zumbrunnen TL Curr Med Res Opin; 2012 Feb; 28(2):271-9. PubMed ID: 22185431 [TBL] [Abstract][Full Text] [Related]
20. Transdermal androgen therapy to augment EPO in the treatment of anemia of chronic renal disease. Brockenbrough AT; Dittrich MO; Page ST; Smith T; Stivelman JC; Bremner WJ Am J Kidney Dis; 2006 Feb; 47(2):251-62. PubMed ID: 16431254 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]